Navigation Links
A single sugar found responsible for an antibody's ability to treat inflammation

For years, researchers have struggled to understand how IVIG worked. It's ability to treat autoimmune diseases seemed to bean apparent contradiction.

Intravenous immunoglobulin (IVIG) is a complex mixture of IgG antibodies made from human plasma that contains the pooled antibodies from thousands of people, and is only FDA-approved to treat a few assorted conditions; nonetheless, practitioners have used it off-label with varied success in patients with lupus, arthritis and asthma, among other autoimmune disorders. In the body, the antibodies in plasma act as part of the immune response to identify and deactivate foreign invaders. When they begin attacking the body's own cells, the same protective immunoglobulins (known as IgG antibodies) can cause autoimmune disorders like lupus, arthritis and asthma. And yet, when IVIG is infused into people with those exact autoimmune conditions, it calms inflammation rather than causes it.

Jeffery Ravetch, Theresa and Eugene M. Lang Professor and head of Rockefeller's Laboratory of Molecular Genetics and Immunology, was struck by this inconsistency. "If IgG triggers autoimmune disease, how could it be pathogenic and therapeutic?" he asked. "We call it the IgG paradox." Six years ago he started an investigation into exactly how IVIG worked, and what he's discovered could one day lead to a whole new class of therapeutics. In a paper published today in the journal Science, Ravetch and his colleagues, Falk Nimmerjahn and Yoshi Kaneko explain what makes IVIG effective: A small fraction of the IgG antibodies in the IVIG solution carry a sugar called sialic acid that is required for its protective ability.

IgG antibodies bind to and activate specific immune cells, with different forms or "subclasses" binding to specific receptors (called Fc receptors) on the immune cell's surface. Antibody subclasses have different abilities to induce inflammation in the body by virtue of their selective ability to engage ei ther activating or inhibitory Fc receptors. Earlier work had shown that IVIG infusion changed this ratio of activating and inhibitory receptors on the cells that trigger inflammation, rendering the pro-inflammatory autoantibodies in autoimmune diseases, like lupus and arthritis, less inflammatory. The next logical step then, Ravetch says, was determining how the IgG molecules in IVIG preparation could have an anti-inflammatory effect.

Because a therapeutic, anti-inflammatory response to IVIG requires a concentration of IgG antibodies that's hundreds of times greater than is normally used for antibody therapy for cancer or infection, for example, Ravetch and his colleagues began to look for something that was only present in IVIG in small amounts. That's how they discovered that just the very terminal sialic acid on the Fc portions of the IgG molecule were the root of the anti-inflammatory activity. When the researchers removed the sialic acid, the molecule retained its structure and its half-life, but it lost its protective abilities. "This is a very interesting condition that's set up," Ravetch says. "IgG can shift from a state that is quite inflammatory to a state that is actively anti-inflammatory by just changing a sugar." This switch occurs during a normal immune response to a foreign substance, shifting the IgG antibodies from an anti-inflammatory state to one that is pro-inflammatory and able to efficiently dispose of the foreign challenge.

To test the theory, Ravetch and his colleagues tried enriching IVIG for the IgG molecules that contained sialic acid. They found that just enriching for this IgG species increased IVIG activity by a factor of ten, while removing it wiped out the therapeutic activity altogether. This discovery, Ravetch says, has potentially huge implications, and his lab is now working to generate a recombinant form of IgG that, by virtue of a sialic acid molecule attached in the right place, will be anti-inflammator y and could act as a novel treatment for autoimmune disorders. "We have the opportunity to make a much better form of IVIG that will work 100 times better and be a pure molecule--to build a much better class of therapeutics based on a property that already exists in nature."


'"/>

Source:Rockefeller University


Related biology news :

1. Opposing fat metabolism pathways triggered by a single gene
2. Basis for DNA ejection from single phage particles
3. Ancient DNA confirms single origin of Malagasy primates
4. No single gene for ageing
5. Natural selection at single gene demonstrated
6. Manipulating single cell receptor alters animal behavior
7. Micro-boxes of water used to study single molecules
8. Recombination protein dynamics observed with single monomer resolution
9. Autoimmune disease triggered if T cells miss a single protein early on
10. Best of both worlds -- Targeting a single gene could inhibit bone decay and stimulate bone growth
11. New nanotechnology able to examine single molecules, aiding in determining gene expression
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/16/2018)... , ... October 16, 2018 , ... Our own cells ... discs in our spine. , So comments interventional spine and pain management specialist Jason ... enzymes and proteins, or stem cells harvested from a patient’s bone marrow are proving ...
(Date:10/13/2018)... ... 2018 , ... HOLLOWAY AMERICA, a stainless steel pressure vessel ... PACK EXPO International in Chicago from October 14 to 17. The annual event ... is a member. , At this year’s PACK EXPO at the McCormick Place ...
(Date:10/11/2018)... ... October 11, 2018 , ... ODSC Europe 2018 - one of Open ... at the event from September 19-22. , As Europe’s largest applied data science ... tracks and 4 days. Attendees were given key insights and hands-on training ...
Breaking Biology News(10 mins):
(Date:10/18/2018)... ... 2018 , ... Predicine, a molecular insights company, announced today ... received accreditation from the College of American Pathologists (CAP) for meeting the highest ... its Shanghai facility last month. The current dual CAP accreditation of its laboratories ...
(Date:10/17/2018)... ... October 17, 2018 , ... ... development solutions for drugs, biologics and consumer health products, today announced that Cornell ... Institute, will present at the annual Partnership Opportunities in Drug Delivery (PODD) meeting ...
(Date:10/16/2018)... (PRWEB) , ... October 16, 2018 , ... ... organizations, attended the first Congressional briefing on a revolutionary technology that effectively treats ... the founder of Infinity Healing, testified on how technology using photobiomodulation (PBM) has ...
(Date:10/13/2018)... ... 12, 2018 , ... The Laser Institute of America ... its 50th birthday in New York’s Times Square today, ahead of its 37th ... , In celebration of its 50 years, LIA showed thanks to the support ...
Breaking Biology Technology: